Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS

BOSTON & SEATTLE--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data for its lead oncogenic driver candidate targeting KRAS G12V, AFNT-111, will be presented at the AACR Special Conference: Targeting Ras.

“We continue to see encouraging data from preclinical studies of AFNT-111 as we progress toward clinical investigation,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. “We have observed high potency and specificity as well as a favorable tolerability profile, which provides encouraging support for our oncogenic driver programs. We look forward to presenting these data at the AACR Special Conference: Targeting Ras in Philadelphia.”

Presentation details are as follows:

• Abstract #A009, Poster Session A: March 6^th 4:45-7:00 pm ET: AFNT-111: a novel TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V - Presenting Authors: Gary Shapiro, Ph.D. and Michele Hoffmann, Ph.D., Affini-T Therapeutics

About Affini-T Therapeutics

Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.